154 related articles for article (PubMed ID: 27916045)
1. [A comparison of efficacy and safety between Chinese generic imatinib versus branded imatinib in patients with newly-diagnosed chronic myeloid leukemia in the chronic phase: a single-center prospective cohort study].
Shi HX; Qin YZ; Lai YY; Huang XJ; Jiang Q
Zhonghua Nei Ke Za Zhi; 2016 Dec; 55(12):922-926. PubMed ID: 27916045
[No Abstract] [Full Text] [Related]
2. [Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics].
Dou XL; Yu L; Qin YZ; Shi HX; Lai YY; Hou Y; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):924-931. PubMed ID: 31856442
[No Abstract] [Full Text] [Related]
3. [Comparison of generic and original imatinib in the treatment of newly diagnosed patients with chronic myelogenous leukemia in chronic phase: a multicenter retrospective clinical study].
Jiang H; Zhi LT; Hou M; Wang JX; Wu DP; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2017 Jul; 38(7):566-571. PubMed ID: 28810322
[No Abstract] [Full Text] [Related]
4. Comparable Efficacy and Safety of Generic Imatinib and Branded Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia With a Consideration of Socioeconomic Characteristics: A Retrospective Study From a Single Center.
Dou X; Qin Y; Lai Y; Shi H; Huang X; Jiang Q
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):e304-e315. PubMed ID: 32209331
[TBL] [Abstract][Full Text] [Related]
5. [A retrospective analysis of the efficacy and safety of imatinib in children with chronic myeloid leukemia during chronic phase].
Zhang LQ; Zheng J; Chen ZP; Li SD; Ma J; Wu RH
Zhonghua Er Ke Za Zhi; 2019 Feb; 57(2):113-117. PubMed ID: 30695885
[No Abstract] [Full Text] [Related]
6. The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia.
Islamagic E; Hasic A; Kurtovic S; Suljovic Hadzimesic E; Mehinovic L; Kozaric M; Kurtovic-Kozaric A
Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):238-240. PubMed ID: 28283298
[TBL] [Abstract][Full Text] [Related]
7. [A prospective, multi-centre clinical trial to evaluate the early clinical efficacy and safety of a generic imatinib in treating patients with chronic phase of chronic myelogenous leukemia].
Jiang Q; Zhao D; Jin J; Wu D; Meng F; Hu J; Liu B; DU X; Liu T; Li Y; Hou M; Han X; Shen Z; Ma J
Zhonghua Xue Ye Xue Za Zhi; 2015 Aug; 36(8):651-5. PubMed ID: 26462633
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: sharing experience of a hemato-oncology center from eastern India.
Phukan A; Mandal PK; Dolai TK
Ann Hematol; 2021 Jan; 100(1):85-96. PubMed ID: 33025163
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.
Gore L; Kearns PR; de Martino ML; Lee ; De Souza CA; Bertrand Y; Hijiya N; Stork LC; Chung NG; Cardos RC; Saikia T; Fagioli F; Seo JJ; Landman-Parker J; Lancaster D; Place AE; Rabin KR; Sacchi M; Swanink R; Zwaan CM
J Clin Oncol; 2018 May; 36(13):1330-1338. PubMed ID: 29498925
[TBL] [Abstract][Full Text] [Related]
10. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
Sawyers CL; Hochhaus A; Feldman E; Goldman JM; Miller CB; Ottmann OG; Schiffer CA; Talpaz M; Guilhot F; Deininger MW; Fischer T; O'Brien SG; Stone RM; Gambacorti-Passerini CB; Russell NH; Reiffers JJ; Shea TC; Chapuis B; Coutre S; Tura S; Morra E; Larson RA; Saven A; Peschel C; Gratwohl A; Mandelli F; Ben-Am M; Gathmann I; Capdeville R; Paquette RL; Druker BJ
Blood; 2002 May; 99(10):3530-9. PubMed ID: 11986204
[TBL] [Abstract][Full Text] [Related]
11. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec.
Eskazan AE; Sadri S; Keskin D; Ayer M; Kantarcioglu B; Demirel N; Aydin D; Aydinli F; Yokus O; Ozunal IE; Berk S; Yalniz FF; Elverdi T; Salihoglu A; Ar MC; Ongoren S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):804-811. PubMed ID: 28847475
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy.
Bonifacio M; Scaffidi L; Binotto G; Miggiano MC; Danini M; Minotto C; Griguolo D; Marin L; Frison L; D'Amore F; Basso M; Sartori R; Tinelli M; Stulle M; Fortuna S; Bonalumi A; Bertoldero G; De Biasi E; Ruggeri M; Semenzato G; Fanin R; Pizzolo G; Krampera M; Tiribelli M
Leuk Res; 2018 Nov; 74():75-79. PubMed ID: 30308414
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and safety of imatinib treatment in children and adolescents with chronic myeloid leukemia: A single-center experience in China.
Deng M; Guan X; Wen X; Xiao J; An X; Yu J
Medicine (Baltimore); 2020 Feb; 99(7):e19150. PubMed ID: 32049841
[TBL] [Abstract][Full Text] [Related]
15. Generic Imatinib Therapy Among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice.
Awidi A; Abbasi S; Alrabi K; Kheirallah KA
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e55-e61. PubMed ID: 28844599
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic Effect of Imatinib Made in Real World to Newly Diagnosed Chronic Myeloid Leukemia].
Ye YF; Lyu XM; Li HL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):456-461. PubMed ID: 33812415
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Generic Dasatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: A Multicenter Prospective Study in China.
Yu W; Du X; Wang W; Lou J; Liu P; Meng L; Jin J
Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):e867-e873. PubMed ID: 35842355
[TBL] [Abstract][Full Text] [Related]
18. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and safety of imatinib in treatment of 151 chronic myeloid leukemia patients].
Zhou L; Wang AH; Wang L; You JH; Li JM; Shen ZX
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):13-7. PubMed ID: 18512309
[TBL] [Abstract][Full Text] [Related]
20. [The clinical analysis of frontline nilotinib vs imatinib therapies for newly diagnosed chronic myeloid leukemia in chronic phase].
Yin H; Chen LF; Cui JK; Xiong YY; You Y; Zou P; Li WM
Zhonghua Nei Ke Za Zhi; 2017 Nov; 56(11):810-815. PubMed ID: 29136709
[No Abstract] [Full Text] [Related]
[Next] [New Search]